Elestat® is a sterile ophthalmic solution containing epinastine that is indicated for the prevention of ocular itching associated with allergic conjunctivitis.
Elestat, or epinastine solution, is used to treat itchiness caused by an eye allergy linked to exposure to tree pollen, grass and plants, animal dander, feathers, dust mites and molds.
Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT ® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS ® (cyclosporine ophthalmic emulsion) 0.05% for dry eye and DIQUAS™ Ophthalmic Solution 3% (diquafosol tetrasodium) for dry eye.
Total product co-promotion and royalty revenue, comprised of royalty revenue from net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0. 05% and co-promotion revenue from net sales of ELESTAT® (epinastine HCl ophthalmic solution) 0. 05%, was $17.5 million for the fourth quarter of 2009, compared to ❋ Unknown (2010)
Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0. 05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0. 05% for dry eye. ❋ Unknown (2010)
Co-promotion revenue from ELESTAT will be dependent on the timing of a launch of a generic form of epinastine, which could occur in 2010. ❋ Unknown (2010)
Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. ❋ Unknown (2010)
Based upon historical timelines and our understanding of the FDA review cycle, we do not expect a generic epinastine product to launch in 2009. ❋ Unknown (2009)
Upon completing an evaluation of the situation Boehringer Ingelheim, the owner of the Elestat patent decided not to pursue or file suit against the companies currently seeking approval of a generic epinastine product. ❋ Unknown (2009)
Recently we have reported that several ANDA filings for a generic version of epinastine were filed with the FDA. ❋ Unknown (2009)
Until a generic epinastine is launched, we will continue to vigorously co-promote Elestat. ❋ Unknown (2009)
I can tell you from an Elestat prospective we have spent a considerable amount of time looking at that situation and the best guidance I can give you is that we think that it's unlikely that a generic epinastine product will be launched in 2009. ❋ Unknown (2009)
® (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis and the co-promotion of ELESTAT ® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis.
® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS ❋ Unknown (2010)
® epinastine HCl ophthalmic solution 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS ❋ Unknown (2010)
® (epinastine HCl ophthalmic solution) 0. 05% for allergic conjunctivitis and royalties based on net sales of RESTASIS
Inspire employs a US sales force for the promotion of AzaSite® (azithromycin ophthalmic solution) 1\% for bacterial conjunctivitis, Elestat® (epinastine HCI … ❋ Unknown (2008)
